GSK finds synergies with global marketing strategyGSK has shifted towards a global marketing model influenced by a Netflix-style approach that aims to match content Share XGSK finds synergies with global marketing strategyhttps://pharmaphorum.com/views-and-analysis/gsk-finds-synergies-with-global-marketing-strategy/
ESMO 2019 roundupThe European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma Share XESMO 2019 rounduphttps://pharmaphorum.com/views-analysis-oncology/esmo-2019-roundup/
GSK aims to get triple therapy approved for asthma in USGlaxoSmithKline and development partner Innoviva have filed a dossier with the FDA, in a bid to get their Share XGSK aims to get triple therapy approved for asthma in UShttps://pharmaphorum.com/news/gsk-bids-to-become-first-asthma-triple-therapy-on-the-us-market/
How to make digital adoption a smooth journeyFour big pharma experts explain the challenges companies face in adopting digital tech and what trends are likely Share XHow to make digital adoption a smooth journeyhttps://pharmaphorum.com/views-analysis-sales-marketing/digital-adoption-smooth-journey/
Towards patient centricity: GSKEmbedding the patient voice into the DNA of a pharmaceutical company isn’t easy – but it is essential. Share XTowards patient centricity: GSKhttps://pharmaphorum.com/patients/towards-patient-centricity-gsk/
Harnessing data and insights for successAhead of the eyeforpharma Awards shortlist announcement this week, we spoke to judge and commercial insights executive Peter Share XHarnessing data and insights for successhttps://pharmaphorum.com/r-d/views-analysis-r-d/harnessing-data-and-insights-for-success/
GSK announces US leadership changesGlaxoSmithKline has poached Merck KGaA’s Maya Martinez-Davis to head up its US Pharmaceuticals division as it announces current Share XGSK announces US leadership changeshttps://pharmaphorum.com/news/gsk-announces-us-leadership-changes/
GSK eyeing industry vet Jonathan Symonds as new chair; reportGlaxoSmithKline is reported to have found the person it wants to replace Sir Philip Hampton as its non-executive Share XGSK eyeing industry vet Jonathan Symonds as new chair; reporthttps://pharmaphorum.com/news/gsk-eyeing-industry-vet-jonathan-symonds-as-new-chair-report/
Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerGlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid Share XRelief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerhttps://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/
